Skóra Magdalena, Gajda Mateusz, Namysł Magdalena, Wordliczek Jerzy, Zorska Joanna, Piekiełko Piotr, Żółtowska Barbara, Krzyściak Paweł, Heczko Piotr B, Wójkowska-Mach Jadwiga
Chair of Microbiology, Faculty of Medicine, Jagiellonian University Medical College, Czysta 18 Street, 31-121 Krakow, Poland.
Department of Microbiology, University Hospital in Krakow, Macieja Jakubowskiego 2 Street, 30-688 Krakow, Poland.
J Fungi (Basel). 2023 Jun 13;9(6):666. doi: 10.3390/jof9060666.
Coronavirus disease 2019 (COVID-19) has been shown to be a favoring factor for aspergillosis, especially in a severe course requiring admission to the intensive care unit (ICU). The aim of the study was to assess the morbidity of CAPA among ICU patients in Poland and to analyze applied diagnostic and therapeutic procedures. Medical documentation of patients hospitalized at the temporary COVID-19 dedicated ICU of the University Hospital in Krakow, Poland, from May 2021 to January 2022 was analyzed. In the analyzed period, 17 cases of CAPA were reported with an incidence density rate of 9 per 10 000 patient days and an incidence rate of 1%. and were isolated from lower respiratory samples. Antifungal therapy was administered to 9 patients (52.9%). Seven patients (77.8%) received voriconazole. The CAPA fatality case rate was 76.5%. The results of the study indicate the need to increase the awareness of medical staff about the possibility of fungal co-infections in ICU patients with COVID-19 and to use the available diagnostic and therapeutic tools more effectively.
2019冠状病毒病（COVID-19）已被证明是曲霉病的一个促发因素，尤其是在需要入住重症监护病房（ICU）的严重病程中。本研究的目的是评估波兰ICU患者中侵袭性肺曲霉病（CAPA）的发病率，并分析所应用的诊断和治疗程序。对2021年5月至2022年1月在波兰克拉科夫大学医院临时COVID-19专用ICU住院患者的医疗记录进行了分析。在分析期间，报告了17例CAPA病例，发病密度率为每10000患者日9例，发病率为1%。 从下呼吸道样本中分离出来。9名患者（52.9%）接受了抗真菌治疗。7名患者（77.8%）接受了伏立康唑治疗。CAPA病死率为76.5%。研究结果表明，有必要提高医务人员对COVID-19的ICU患者发生真菌合并感染可能性的认识，并更有效地使用现有的诊断和治疗工具。
